Hepion pharmaceuticals discovers novel rencofilstat action in liver cancer

- research study demonstrates regulation of chromatin structure and cancer gene expression – - findings to augment clinical trial in liver cancer - edison, n.j., sept. 19, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced new research findings uncovering a previously unknown mechanism by which hepion's lead drug candidate, rencofilstat, may exert anti-cancer activity.
HEPA Ratings Summary
HEPA Quant Ranking